-

Helix Appoints Genentech and Flatiron Health Vet Hylton Kalvaria as SVP of Life Sciences

SAN MATEO, Calif.--(BUSINESS WIRE)--Helix, the leading population genomics company in the nation, today announced that Hylton Kalvaria has joined its leadership team as senior vice president (SVP) of Life Sciences. Kalvaria will oversee partnerships leveraging the unique and growing clinico-genomic datasets of Helix with life sciences customers.

Kalvaria brings a wealth of executive experience and healthcare data expertise gleaned from more than a decade of holding positions of increasing responsibility within the life sciences industry. He was most recently President and Chief Commercial Officer at clinical natural language processing startup Mendel AI. Kalvaria also served in leadership roles at Verana Health, Flatiron Health, and Genentech.

“We’re thrilled with the momentum we’ve seen in 2023 and the start of 2024, finalizing partnerships with some of the top health systems, life sciences and public health organizations in the country,” said James Lu, MD, Ph.D., CEO and co-founder of Helix. “Strengthening our leadership team with someone as talented and passionate as Hylton only further positions Helix to ensure the power of genomics is used to improve healthcare outcomes on the largest possible scale.”

For the last several years, Helix has been helping life science companies bring innovative, personalized therapies to patients faster through the application of their real-world clinico-genomic data and extensive health systems network. Helix’s comprehensive platform of solutions can be used to access data in a wide range of disease-specific clinico-genomic datasets to accelerate the drug development process from discovery to commercialization.

“I’m proud to be part of a company doing meaningful work that has the potential to affect positive change for all stakeholders in the healthcare ecosystem,” Hylton Kalvaria said. “The sheer number of new drugs in development that leverage genetic approaches is driving massive demand for the kinds of datasets that Helix has become known for. Helix is committed to partnering with life science companies to leverage real-world clinico-genomic data across the drug development lifecycle.”

About Helix

Helix is the leading population genomics company. Helix enables health systems, public health organizations and life sciences companies to accelerate the integration of genomic data into patient care and therapeutic development. Learn more at www.helix.com.

Contacts

Patrick Schmidt
press@helix.com

Helix


Release Versions

Contacts

Patrick Schmidt
press@helix.com

Social Media Profiles
More News From Helix

The Ohio State University Wexner Medical Center and Helix Partner to Launch the Largest Precision Health Initiative in Ohio

COLUMBUS, Ohio & SAN MATEO, Calif.--(BUSINESS WIRE)--The Ohio State University Wexner Medical Center and Helix, the leading precision health organization in the nation, are launching the largest precision health initiative in Ohio, aimed at driving better health outcomes and more personalized care for all individuals in the state. The program, named Ohio State Genomic Health, will enroll 100,000 participants over four years and will provide important information about potential risks for health...

Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data

SAN MATEO, Calif.--(BUSINESS WIRE)--Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with Recursion Pharmaceuticals (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to industrialize drug discovery. Recursion will have access to de-identified clinico-genomic data, collected from research participants who consent to participate in Helix’s extensive research network, wh...

Helix Launches Clinico-Genomic Datasets for Cardiovascular, Metabolic, Immunology and Inflammation Disorders

SAN MATEO, Calif.--(BUSINESS WIRE)--Helix, the leading population genomics company, is launching new clinico-genomic datasets to enable life science companies to drive precision medicine drug discovery and development. Built through Helix’s extensive health system partnerships, these population-scale cohorts consist of full longitudinal clinical and genomic records that span multiple therapeutic areas including Cardiovascular, Immunology & Inflammation, Metabolic conditions and more. “Life...
Back to Newsroom